

Half-Year Report
JANUARY–JUNE

2021

H1

Contents

MorphoSys Group: Half-Year Report January – June 2021

3	Summary
6	Interim Group Management Report
6	Operating Business Performance
13	Strategy and Group Management
13	Corporate Developments
13	Subsequent Events
14	General Business and Market Environment
14	MorphoSys Shares
15	Intellectual Property
15	Human Resources
16	Financial Analysis
22	Interim Consolidated Financial Statements
22	Consolidated Statement of Profit or Loss (IFRS)
23	Consolidated Statement of Comprehensive Income (IFRS)
24	Consolidated Balance Sheet (IFRS)
26	Consolidated Statement of Changes in Stockholder's Equity (IFRS)
28	Consolidated Statement of Cash Flows (IFRS)
30	Notes to the Consolidated Financial Statements

Summary of the Second Quarter of 2021

Operating Highlights for the Second Quarter of 2021

- On April 19, 2021, MorphoSys and Incyte announced the first patient had been dosed in the placebo-controlled phase 3 inMIND study. The study is evaluating the efficacy and safety of tafasitamab in combination with lenalidomide and rituximab compared to lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).
- On May 11, 2021, MorphoSys and Incyte announced the first patient had been dosed in the pivotal phase 3 frontMIND study. The study is evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL).
- On June 2, 2021, MorphoSys announced its plans to acquire Constellation Pharmaceuticals to accelerate its growth strategy by adding two mid- to late-stage product candidates, pelabresib (CPI-0610) and CPI-0209 and bolster its position in hematology-oncology and expand into solid tumors. In order to fund this acquisition, MorphoSys entered into a strategic funding partnership with Royalty Pharma.
- On June 4-8, 2021, MorphoSys presented new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab (Monjuvi®) in combination with lenalidomide in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
- On June 16, 2021, MorphoSys announced it had filed a tender offer, including an offer to purchase and the terms of the tender offer, with the U.S. Securities and Exchange Commission to purchase all outstanding shares of Constellation Pharmaceuticals, Inc.
- On June 25, 2021, MorphoSys and Incyte announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the conditional marketing authorization for tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

Financial Results for the First Half-Year of 2021

- Group revenues in the first half-year of 2021 reached € 85.4 million (H1 2020: € 269.7 million), and operating expenses amounted to € 171.2 million (H1 2020: € 118.2 million).
- Cash and investments as of June 30, 2021 totaled € 1,129.2 million (December 31, 2020: € 1,244.0 million).
- MorphoSys updated its financial guidance for the 2021 financial year on July 26, 2021. Group revenues changed from a range of € 150 million to € 200 million to a range of € 155 million to € 180 million. Group operating expenses, which are comprised of research and development, selling as well as general and administrative expenses, are expected to be in the range of € 435 million to € 465 million (previously € 355 million to € 385 million), which include operating expenses for Constellation Pharmaceuticals starting July 15, 2021. The revised Group operating expenses range also include one-time transaction related costs of € 36 million related to the agreements with Constellation Pharmaceuticals and Royalty Pharma. Research and Development expenses are anticipated to comprise between 52% to 57% of Group operating expenses (previously 45% to 50%), excluding the one-time transaction costs.


Corporate Developments

- The MorphoSys AG Annual General Meeting on May 19, 2021, re-elected Dr. Marc Cluzel, Sharon Curran and Krisja Vermeylen to the Company's Supervisory Board. Due to the ongoing restrictions related to the COVID-19 pandemic, the 2021 Annual General Meeting was also held as a virtual meeting without the physical presence of shareholders or their proxies, as in the prior year, and was available to registered shareholders as a live broadcast on the Internet.


Significant Events After the End of the Second Quarter of 2021

- For the detailed effects and events in connection with the Constellation Pharmaceuticals acquisition, please refer to section 13 of the notes to this half-year report.

Our Clinical Pipeline as of June 30, 2021



Clinical Programs Developed by Partners (Selection)



Pipeline products in development stage phases 1-3 are under clinical investigation and there is no guarantee any investigational product will be approved by regulatory authorities.

Interim Group Management Report: January 1 – June 30, 2021

Operating Business Performance

Acquisition of Constellation Pharmaceuticals

MorphoSys announced on June 2, 2021, its plans to acquire Constellation Pharmaceuticals, Inc. (“Constellation”) for US\$ 34.00 per share in cash, which represents a total equity value of US\$ 1.7 billion. The transaction was unanimously approved by the Management Board and Supervisory Board of MorphoSys as well as by the Board of Directors of Constellation. The acquisition closed on July 15, 2021.

Constellation is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with various forms of cancer. Constellation’s two lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a second-generation EZH2 inhibitor, are in late- and mid-stage clinical trials respectively and have broad therapeutic potential to offer meaningful benefits to patients with various hematological and solid tumors. Pelabresib has the potential to be a first- and best-in-class BET inhibitor and is currently in a Phase 3 clinical trial for myelofibrosis, a bone marrow cancer that disrupts the body’s normal production of blood cells. The EZH2 inhibitor CPI-0209 is currently in Phase 2 with best-in-class potential for treating hematological and solid tumors. Constellation’s pipeline also includes numerous preclinical compounds.

MorphoSys also announced that it has entered into a long-term strategic funding partnership with Royalty Pharma (Royalty Pharma plc and its subsidiaries) in conjunction with the Constellation transaction. The terms of the agreement between MorphoSys and Royalty Pharma provide for the following, under certain conditions and upon closing of the transaction with Constellation:

- US\$ 1.425 billion upfront payment: Royalty Pharma will make a US\$ 1.425 billion upfront payment to MorphoSys, supporting its growth strategy. The proceeds will be used to support the financing of the Constellation transaction and development of the combined company’s pipeline.
- US\$ 350 million development funding bonds: Royalty Pharma USA Inc. will provide MorphoSys with access to up to US\$ 350 million in Development Funding Bonds with the flexibility to draw over a one-year period.
- Milestone payments: Royalty Pharma will make additional payments of up to US\$ 150 million to MorphoSys upon reaching clinical, regulatory and commercial milestones for otilimab, gantenerumab and pelabresib.
- Royalties and milestones: Royalty Pharma will have the rights to receive 100% of MorphoSys’ royalties on net sales of Tremfya[®], 80% of future royalties and 100% of future milestone payments on otilimab, 60% of future royalties on gantenerumab, and 3% on future net sales of Constellation’s clinical stage assets (pelabresib and CPI-0209).
- Equity investment: After completion of the transaction and subject to the required approvals of the management board (Vorstand) and the supervisory board (Aufsichtsrat) of MorphoSys, Royalty Pharma is expected to invest US\$ 100 million in a cash capital increase of MorphoSys under an authorization to exclude subscription rights of existing shareholders. The new MorphoSys shares will be listed on the Frankfurt Stock Exchange.

An Integration Project Team headed by Barbara Krebs-Pohl, PhD, as Chief Integration Officer has started work and will organize and support the integration of Constellation. Constellation will continue to operate as an independent subsidiary of MorphoSys until further notice, and MorphoSys expects the following benefits from the acquisition:

- Accelerates growth strategy with exciting mid- to late-stage product candidates: The transaction accelerates MorphoSys' strategy to grow through proprietary drug development and commercialization. Constellation's lead product candidates, pelabresib and CPI-0209, have broad potential, with expected approvals across a range of oncology indications in the coming years. Constellation's lead compounds fit well with MorphoSys' proven clinical development, regulatory and commercial capabilities, and MorphoSys is well positioned to rapidly advance and unlock the potential of the Constellation portfolio.
- Bolsters position in hematology-oncology and expands into solid tumors: Constellation adds an attractive, complementary pipeline of highly innovative early to late-stage cancer therapy candidates, augmenting MorphoSys' existing pipeline in hematologic malignancies and expanding into potential therapies for solid tumors.
- Strengthens cutting-edge research and development organization: The transaction leverages MorphoSys' expertise in biologics and Constellation's expertise in epigenetics and small molecule discovery platforms to develop a broad range of oncology therapies. Constellation adds exciting, pioneering science and attractive preclinical compounds targeting epigenetic regulators. Together, MorphoSys' and Constellation's highly talented research and development teams will strengthen earlier stage and emerging science to bring exciting new cancer therapies to patients.
- Anchored by strategic funding partnership: Royalty Pharma's strategic funding partnership will fuel the expansion of the combined company's capabilities to help accelerate the development, approval and commercial reach of breakthrough cancer treatments. This long-term commitment will help deliver significant value to all stakeholders.

Consummation of the tender offer was subject to various conditions including a minimum tender of at least a majority of outstanding Constellation shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and the receipt of any approvals or clearances required to be obtained under the applicable antitrust laws, and other customary conditions. The full transaction was completed on July 15, 2021.

Development of Tafasitamab

MorphoSys' commercial activities are currently focused on Monjuvi[®] (tafasitamab-cxix) in the United States. Tafasitamab is a humanized monoclonal antibody directed against the CD19 antigen. CD19 is selectively expressed on the surface of B-cells, a group of white blood cells. CD19 enhances B-cell receptor signaling, which is an important factor in B-cell survival and growth, making CD19 a potential target structure for the treatment of B-cell malignancies.

On July 31, 2020, Monjuvi[®] in combination with lenalidomide received accelerated FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplantation (ASCT). MorphoSys co-commercializes Monjuvi[®] with partner Incyte in the United States.

Commercial Performance of Tafasitamab

During the first half of 2021, Monjuvi[®] demonstrated sequential sales growth in the second quarter despite continued COVID-19 headwinds - driven by underlying double-digit demand growth as shown in vials and momentum exiting June. The company, along with partner Incyte, has in aggregate received orders from more than 700 treatment sites. Outpatient share in the community setting continues to show strong traction and now accounts for 70% of customers.

Overall, commercial performance in the first half of the year continued to be adversely impacted by COVID-19. As vaccination rates have increased there has been a gradual easing of restrictions at sites of care. This has allowed sales teams to engage in more face-to-face meetings with physicians and contributed to the positive momentum we observed in June. Many larger facilities, however, are opening at a slower pace than community health centers. As of April 1, 2021, Monjuvi[®] was granted a J-code, which will further simplify reimbursement for some treatment centers.

Regulatory Progress of Tafasitamab

On January 5, 2021, MorphoSys and Incyte announced that the Swiss Agency for Therapeutic Products (Swissmedic) had accepted the marketing authorization application (MAA) for tafasitamab and on January 12, 2021, MorphoSys and Incyte announced that Health Canada had accepted the New Drug Submission (NDS) for tafasitamab. Both applications are based on data from the L-MIND study of tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory DLBCL and data from the RE-MIND study, a retrospective observational study of relapsed or refractory DLBCL. Both applications seek approval for tafasitamab, in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplantation (ASCT). Incyte has exclusive marketing rights for tafasitamab outside the U.S. and if approved, Incyte will receive marketing approval in Switzerland and Canada.

On May 20, 2020, MorphoSys and Incyte announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). As in the U.S., the marketing authorization application submitted by MorphoSys was based on data from the L MIND study and supported by RE-MIND.

On June 25, 2021, MorphoSys and Incyte announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the conditional

marketing authorization for tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). The CHMP opinion to recommend the use of tafasitamab is now being reviewed by the European Commission, which has the authority to grant marketing authorization for medicinal products in the European Union (EU). If approved, tafasitamab would be commercialized in the EU under the brand name Minjuvi®. Incyte has exclusive marketing rights for tafasitamab outside the U.S., and if approved, Incyte will receive the marketing authorization in Europe.

Research and Development

The acquisition of Constellation Pharmaceuticals is anticipated to accelerate the growth of the MorphoSys pipeline with the addition of two compounds in mid- to late-stage clinical development. Pelabresib (CPI-0610) and CPI-0209 will strengthen MorphoSys' position in hematology-oncology and enable it to expand into potential therapies for solid tumors. Constellation's research and development capabilities are complementary to MorphoSys' own capabilities and set the stage for the development of new cancer therapies for patients.

MorphoSys' research and development activities are currently focused on the following clinical candidates:

- Tafasitamab (MOR208, formerly XmAb5574) is a humanized monoclonal antibody directed against the CD19 antigen. CD19 is selectively expressed on the surface of B-cells, which belong to a group of white blood cells. CD19 enhances B-cell receptor signaling, which is an important factor in B-cell survival and growth. CD19 is a potential target structure for the treatment of B-cell malignancies.
- Felzartamab (MOR202/TJ202) is a recombinant human monoclonal HuCAL-IgG1-antibody directed against a unique epitope of the target molecule CD38. CD38 is a surface antigen broadly expressed on malignant myeloma cells as well as on antibody-producing plasmablasts and plasma cells, the latter playing an important role in the pathogenesis of antibody-mediated autoimmune diseases.
- Pelabresib (CPI-0610) is a BET inhibitor with an epigenetic mechanism of action to address serious unmet medical needs in patients with various forms of cancer.
- CPI-0209 is a second-generation EZH2 inhibitor with an epigenetic mechanism of action that has been designed to achieve comprehensive target coverage through extended on-target residence time. The compound has demonstrated more potent anti-tumor activity compared with first-generation EZH2 inhibitors in preclinical models of multiple cancer types. It does not induce its own metabolism, which has been an issue with other EZH2 inhibitors.

In addition to MorphoSys' own pipeline, the following programs, among others, are being further developed by our partners:

- Otilimab (formerly MOR103/GSK3196165) is a fully human HuCAL-IgG1-antibody directed against granulocyte-monocyte colony-stimulating factor (GM-CSF). Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad range of anti-inflammatory therapies such as rheumatoid arthritis (RA). Otilimab was fully out-licensed to GlaxoSmithKline (GSK) in 2013. As part of the Constellation financing agreement, Royalty Pharma will receive 80% of future royalties and 100% of future milestone payments on Otilimab.
- MOR202/TJ202 (see above) is also being further developed by I-Mab Biopharma for China, Taiwan, Hong Kong and Macau where, if approved, it may also be commercialized.
- MOR210 is a human antibody directed against C5aR, derived from MorphoSys' HuCAL library. C5aR, the receptor of complement factor C5a, is being investigated as a potential new drug target in the fields of immuno-oncology and autoimmune diseases. In November 2018, MOR210/TJ210 was out-licensed to I-Mab for China and certain other countries in Asia.

- Gantenerumab, an antibody targeting amyloid-beta, is being developed by MorphoSys' partner Roche as a potential treatment for Alzheimer's disease. As part of the Constellation financing agreement, Royalty Pharma will receive 60% of future royalties on Gantenerumab.
- In addition to the programs listed above, MorphoSys and its partners are pursuing several programs in various stages of research and clinical development.

Proprietary Clinical Development

Studies of Tafasitamab

The clinical development of tafasitamab is focused on non-Hodgkin's lymphoma (NHL). In DLBCL, MorphoSys is aiming at positioning tafasitamab as a backbone therapy for all patients suffering from DLBCL, regardless of treatment line or potential combination therapy. Both the L-MIND and B-MIND studies concentrate on those patients with r/r DLBCL who are not candidates for high-dose chemotherapy (HDC) and ASCT. Treatment options for this group of patients were limited prior to the U.S. approval of tafasitamab. Additionally, the firstMIND study, included patients with newly diagnosed DLBCL and paved the way for the frontMIND study, a pivotal phase 3 trial in first-line patients, which began in May 2021.

In June 2021, MorphoSys and Incyte announced new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab (Monjuvi[®]) in combination with lenalidomide in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The new results - based on an October 30, 2020 data cut-off - build on previous findings showing durable responses and a consistent safety profile of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy. A total of 80 out of 81 enrolled study patients receiving tafasitamab plus lenalidomide were included in the efficacy analysis at approximately three years follow-up (>35 months). The long-term analysis, as assessed by an independent review committee (IRC), showed that patients treated with tafasitamab plus lenalidomide had an overall response rate (ORR) of 57.5%, including a complete response (CR) rate of 40%. Additionally, the median duration of response (DoR) was 43.9 months, with a median overall survival (OS) of 33.5 months and median progression free survival (PFS) of 11.6 months.

The phase 2/3 study, B-MIND, initiated in September 2016, is evaluating the safety and efficacy of administering tafasitamab in combination with the chemotherapeutic agent bendamustine in comparison to administering the anticancer drug rituximab plus bendamustine in patients with r/r DLBCL who are not candidates for high-dose chemotherapy and autologous stem cell transplantation. The study has been in the phase 3 part since mid-2017. MorphoSys expects top-line results from the study to be available in 2022.

In addition to the previously mentioned clinical development in r/r DLBCL, MorphoSys initiated a randomized phase 1b clinical trial in first-line therapy in patients with DLBCL (firstMIND) in late 2019. The study completed enrollment earlier than anticipated and is evaluating the safety (primary endpoint) and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in combination with R-CHOP (the current standard of care) in patients with newly diagnosed DLBCL. This study paved the way for frontMIND, a pivotal phase 3 trial of tafasitamab in first-line DLBCL. The frontMIND study dosed the first patient on May 11, 2021 and plans to enroll up to 880 patients.

In addition to these combination studies in DLBCL, MorphoSys has been investigating tafasitamab in a phase 2 combination study in chronic lymphocytic leukemia (CLL) or small B-cell lymphoma (SLL) since December 2016. The COSMOS study, in particular, is evaluating the safety of tafasitamab in combination with the anticancer drugs idelalisib (Cohort A) or venetoclax (Cohort B). The study enrolled patients who either did not respond to or did not tolerate prior therapy with a Bruton tyrosine kinase inhibitor. Data from the primary analysis of both cohorts were presented at the ASH conference in Orlando in December 2019.

Incyte is responsible for the initiation of a combination study of its PI3K delta inhibitor piasclisib with tafasitamab in relapsed or refractory B-cell malignancies (TopMIND) and to initiate a pivotal phase 3 study (inMIND) in patients with relapsed or refractory follicular lymphoma (r/r FL) as well as in patients with relapsed or refractory marginal zone follicular lymphoma (MZL). This global, randomized trial of approximately 600 patients has started in April 2021 and will compare the safety and efficacy of tafasitamab in combination with rituximab and lenalidomide to the safety and efficacy of rituximab in combination with lenalidomide.

In November 2020, MorphoSys and Incyte announced a clinical collaboration agreement with Xencor to evaluate the combination of tafasitamab, lenalidomide and plamotamab – a tumor-targeted bispecific antibody from Xencor, which has both a CD20-binding domain and a cytotoxic T-cell binding domain (CD3) – in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL and relapsed or refractory follicular lymphoma (FL). Under the agreement, the companies plan to initiate a phase 1/2 trial evaluating the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory DLBCL. The companies are also working on plans to evaluate this combination in relapsed or refractory FL and first-line DLBCL patients in multiple phase 1b trials. MorphoSys and Incyte will provide tafasitamab for the studies, which are sponsored and funded by Xencor and planned to be conducted in North America, Europe and the Asia-Pacific region.

Studies of Felzartamab

Felzartamab is currently being evaluated by MorphoSys in autoimmune diseases. In November 2017, MorphoSys entered into a regional license agreement with I-Mab for development in China, Hong Kong, Macau and Taiwan. I-Mab is currently pursuing development in multiple myeloma.

In October 2019, MorphoSys initiated a phase 1/2 trial for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease affecting the kidneys. The proof-of-concept study, called M-PLACE, is an open-label, multi-center study and will primarily evaluate the safety and tolerability of felzartamab. Secondary endpoints include the effect of felzartamab on serum antibodies to PLA2R and evaluation of the immunogenicity and pharmacokinetics of felzartamab; an exploratory objective is to determine clinical efficacy. In November 2020, the safety run-in phase of the study ended and the further enrollment phase was opened. In February 2021, MorphoSys achieved the First Treated Patient milestone in the phase 2 New-PLACE study, which in coherence with M-PLACE, is designed to identify the optimal felzartamab dosing schedule for the treatment of patients with anti-PLA2R-positive membranous nephropathy.

The following ongoing Constellation Pharmaceuticals' clinical studies, will presumably continue after the acquisition was completed on July 15, 2021:

Studies of Pelabresib

Pelabresib is in two clinical trials for the treatment of myelofibrosis (MF), a bone marrow cancer that disrupts the normal production of blood cells in the body.

MANIFEST, a global, multi-center, open-label phase 2 study in patients with myelofibrosis is testing pelabresib:

- as monotherapy in MF patients who are refractory to or intolerant of, and are no longer on, ruxolitinib (Arm 1);
- as add-on to ruxolitinib in MF patients who have had a suboptimal response to ruxolitinib or have experienced disease progression (Arm 2);
- in combination with ruxolitinib in MF patients who are JAK-inhibitor-naïve (Arm 3);
- as monotherapy in patients with high-risk essential thrombocythemia who are intolerant of, or refractory to, hydroxyurea (Arm 4)).

MANIFEST-2, a global, double-blind, randomized Phase 3 clinical study is evaluating pelabresib in combination with ruxolitinib versus placebo plus ruxolitinib in JAK-inhibitor-naïve patients with primary myelofibrosis or post-ET or post-PV myelofibrosis who have splenomegaly and symptoms requiring therapy.

Study of CPI-0209

Patient enrollment in a Phase 1/2 clinical trial of CPI-0209 is ongoing and patients are dosed in the Phase 1 dose escalation portion of the trial. The phase 1 portion of the trial is evaluating CPI-0209 as a monotherapy in patients with advanced solid tumors. After determining the recommended phase 2 dose for CPI-0209, which is expected in 2021, it is intended to pursue expansion arms in selected tumor indications as well as combination therapy development.

Clinical Development Through Partners

Studies of Otilimab

Otilimab (MOR103/GSK3196165), a fully human HuCAL IgG1 antibody directed against GM-CSF, was fully out-licensed to GSK in 2013. In mid-2019, GSK announced the initiation of a phase 3 program in rheumatoid arthritis (RA) called ContrASt. The program includes three pivotal studies and a long-term extension study and is evaluating the antibody in patients with moderate to severe RA. GSK also initiated a clinical trial (OSCAR) in 2020 to evaluate the efficacy and safety of otilimab in patients with severe pulmonary COVID 19-associated disease. GSK reported preliminary results of the OSCAR trial in February 2021. As these data suggest important clinical benefit in a predefined subgroup of high-risk patients and an urgent unmet medical need, GSK has amended the OSCAR study to expand this cohort and confirm these potentially significant findings. The dosing of the first patient in the expanded study triggered milestone payments to MorphoSys totaling € 16 million.

Studies of Gantenerumab

In June 2018, Roche initiated a new phase 3 development program for patients with Alzheimer's disease. The program consists of two phase 3 trials - GRADUATE 1 and GRADUATE 2 - which are expected to enroll more than 2,000 patients in up to 350 study centers in more than 30 countries worldwide. The two multi-center, randomized, doubleblinded, placebo-controlled studies are investigating the efficacy and safety of gantenerumab in patients with early (prodromal to mild) Alzheimer's disease. The primary endpoint for both studies is the assessment of the signs and symptoms of dementia, measured as the clinical dementia rating sum of boxes (CDR-SOB) score. Both studies have an estimated primary completion date in 2022. Patients receive a significantly higher dose of gantenerumab than in Roche's previous trials as a subcutaneous injection.

Studies of Felzartamab (MOR202/TJ202)

In November of 2017, MorphoSys and I-Mab signed a regional license agreement for the development and commercialization of MOR202/TJ202 in China, Hong Kong, Taiwan and Macau. Under this agreement, I-Mab received exclusive rights in the agreed regions.

On April 27, 2020, MorphoSys and I-Mab announced the dosing of the first patient in a phase 3 clinical study in mainland China to evaluate MOR202/TJ202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (r/r MM). The study (NCT03952091) is a randomized, open-label, controlled, multi-center study to evaluate the efficacy and safety of the combination of felzartamab, lenalidomide and dexamethasone versus the combination of lenalidomide and dexamethasone in patients with r/r MM who have received at least one prior line of treatment. This multi-center study was previously initiated in April 2019 at study sites in Taiwan and has now officially started in mainland China as part of a coordinated

effort to accelerate the study. I-Mab is also evaluating felzartamab as a third-line therapy in patients with r/r MM in a phase 2 trial that began in March 2019. Both studies are considered pivotal in the region.

On June 25, 2021, I-Mab announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) had approved the Investigational New Drug (IND) application to initiate a phase 1b study with felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus (SLE). This new phase 1b study with felzartamab is a multi-center study to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in patients with SLE in China.

Study of MOR210/TJ210

In November 2018, MorphoSys announced that it had entered into an exclusive strategic collaboration and regional license agreement with I-Mab for exclusive rights to develop and commercialize MOR210/TJ210 in China, Hong Kong, Macau, Taiwan and South Korea.

On January 25, 2021, MorphoSys and I-Mab announced the dosing of the first patient in the United States in a phase 1 dose-finding study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MOR210/TJ210 as monotherapy in patients with relapsed or refractory advanced solid tumors. The phase 1 clinical trial is an open-label, multiple dose-group, dose-finding study in multiple centers across the U.S.

Strategy and Group Management

The acquisition of Constellation accelerates the growth strategy and expands the pipeline in hematology-oncology as outlined in the 2020 Annual Report starting on page 53. Future group management will be adjusted to reflect operations of the combined companies.

Corporate Developments

The MorphoSys AG Annual General Meeting on May 19, 2021, re-elected Dr. Marc Cluzel, Sharon Curran and Krisja Vermeylen to the Company's Supervisory Board. Due to the ongoing restrictions related to the COVID-19 pandemic, the 2021 Annual General Meeting, as in the prior year, was also held as a virtual meeting without the physical presence of shareholders or their proxies and was available to registered shareholders as a live visual and audio broadcast on the Internet.

Subsequent Events

For the detailed effects and events in connection with the Constellation Pharmaceuticals acquisition, please refer to section 13 of the notes to this half-year report.

General Business and Market Environment

Economic Trends

The International Monetary Fund (IMF) sees an end to the corona crisis from an economic perspective for industrialized countries. Thanks to vaccinations and stimulus packages, the global economy is projected to grow by 6% this year; 0.5 percentage points higher than assumed in January 2021. Growth in 2021 will be driven primarily by a strong recovery in the U.S., the world's largest economy. The IMF is forecasting growth in economic output in the current year of 3.6% in Germany, and by as much as 4.4% in the eurozone. The IMF raised and updated its annual forecast for the U.S. in July to 7.0%.

Stock markets worldwide began 2021 on a note of optimism. At the end of the first half-year, the German DAX index closed 13.1% higher, followed by the MDAX index for medium-sized companies with an increase of 10.0%, and the TecDAX technology index of +9.8%. Biotech stocks benefitted as well from the gradual approval and application of vaccines against the SARS-CoV 2 virus, as demonstrated, for example, by the performance of the Nasdaq Biotech Index, which closed higher by 8.8% after the first half-year.

Sector Developments

In the first half of 2021, numerous medical conferences were held where several companies in the sector presented their research results. As a result of the travel and meeting restrictions due to the COVID-19 pandemic, these conferences were held exclusively virtually. Among other events, the world's largest oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, was held on June 4-8, 2021 as a virtual conference, as was the leading European conference in the field of hematology, the Annual Meeting of the European Hematology Association (EHA), which was held on June 9-17, 2021. On June 18-22, the 16th International Conference on Malignant Lymphoma (ICML) also took place virtually. MorphoSys presented clinical results of tafasitamab at all three medical conferences. MorphoSys also participated in five investor conferences in May and June of 2021.

MorphoSys Shares

The shares of MorphoSys AG were not able to benefit from the economic upturn described above. After starting the 2021 trading year at € 94.02, the shares temporarily rose above € 100 at the end of January. In the following months, the share price fell and reached its low of € 63.02 on June 2, 2021, when the acquisition of Constellation Pharmaceuticals was announced. The shares closed the first half of 2021 on June 30 at € 65.42.

Intellectual Property

In the first six months of 2021, MorphoSys continued to consolidate and expand the patent protection of its development programs and growing technology portfolio, and thereby the Company's key value drivers.

Currently, the Company has approximately 70 different proprietary patent families worldwide, in addition to the numerous patent families it is pursuing in collaboration with its partners.

Human Resources

On June 30, 2021, the MorphoSys Group had 607 employees (December 31, 2020: 615). In the first six months of 2021, the MorphoSys Group employed an average of 608 people (H1 2020: 518).

Financial Analysis

By virtue of MorphoSys' business model, the COVID-19 pandemic has had limited impact on MorphoSys' net assets and financial position in the first six months of 2021. The COVID-19 pandemic, however, has had a negative impact on the results of operations in the first six months of 2021, specifically on lower than expected sales of Monjuvi®. In addition, the adherence to the time schedule of the clinical studies was associated with higher expenses. There have been no material asset impairments that have been recognized in connection with COVID-19.

MorphoSys reports the key financial figures – revenues, operating expenses and percentage of research and development expenses included therein – relevant for internal management purposes in interim statements. Their presentation is supplemented accordingly if other areas of the income statement or balance sheet during the quarter are affected by material business transactions.

As of the first quarter of 2021, the previous segment information "Proprietary Development" and "Partnered Discovery" is no longer presented as part of the reporting. For further information, please refer to Note 1.

Revenues

Group revenues in the first half-year amounted to € 85.4 million (H1 2020: € 269.7 million). The lower revenues were primarily a result of the collaboration and license agreement concluded with Incyte in 2020. A total of € 27.8 million (H1 2020: € 0 million) of the Group's revenues were from the recognition of Monjuvi® product sales in the U.S.

Success-based payments including royalties accounted for 50% or € 43.1 million (H1 2020: 9% or € 23.1 million) of total revenues. On a regional basis, MorphoSys generated 76% or € 65.0 million of its commercial revenues from product sales and with biotechnology and pharmaceutical companies or non-profit entities in North America and 24% or € 20.4 million with partners primarily located in Europe and Asia. In the same period of the previous year, these percentages were 99% and 1%, respectively. 62% of total Group revenues were generated with customers Janssen, GSK and Incyte (H1 2020: 99% with Incyte, Janssen and I-Mab).

Cost of Sales

Cost of sales in the first six months of 2021 amounted to € 15.2 million (H1 2020: € -4.0 million) and consisted primarily of expenses related to the provision of services in the course of transferring projects to customers and to the acquisition and production costs of inventories recognized as an expense, mainly for Monjuvi®. In 2020, the impairment to net realizable value of zero on the antibody material (tafasitamab) derived from fermenter runs recognized in prior periods was reversed due to the market approval of tafasitamab. This could now be utilized for commercialization and therefore represented inventory and resulted in income. This impairment reversal was recognized in cost of sales and overcompensated for the expenses incurred in the first six months of financial year 2020, which is why cost of sales showed an income in total.

Operating Expenses

Research and Development Expenses

Research and development expenses amounted to € 73.8 million in the first six months of 2021 (H1 2020: € 52.4 million). Expenses in this area consisted primarily of expenses for external laboratory services of € 36.9 million (H1 2020: € 13.1million), personnel expenses of € 22.7 million (H1 2020: € 14.4 million) and expenses for amortization of intangible assets of € 2.9 million (H1 2020 € 16.2 million). The increase in research and development expenses relate mainly to the commencement of different clinical trials for tafasitamab and felzartamab. In 2020, expenses for intangible assets included a total of € 13.7 million in impairment losses related to the in-process R&D program MOR107 and to a license.

Selling Expenses

Selling expenses amounted to € 56.6 million in the first six months of 2021 (H1 2020: € 42.1 million). This item was comprised mainly of personnel expenses of € 31.2 million (H1 2020: € 20.6 million) and expenses for external services of € 23.0 million (H1 2020: € 19.8 million). Selling expenses also included all expenses for services provided by Incyte as part of the joint U.S. sales activities for Monjuvi®. Selling expenses in the first six months of 2020 included preparatory activities and thus monthly increasing expenses of both companies for the commercialization of Monjuvi®, the sales launch of which started with the market approval at the end of July 2020, which is why expenses were lower than in the first six months of 2021.

General and Administrative Expenses

Compared to the same prior-year period, general and administrative expenses increased to € 40.8 million (H1 2020: € 23.9 million). This item mainly included expenses for external services of € 22.8 million (H1 2020: € 6.4 million) and personnel expenses of € 13.7 million (H1 2020: € 14.4 million). The expenses for external services in 2021 include transaction costs in connection with the acquisition of Constellation and the closing of the related agreements with Royalty Pharma in the amount of € 18.8 million.

Other Income/Finance Income/Finance Expenses

Other income amounted to € 2.8 million in the first six months of 2021 (H1 2020: € 10.0 million) and resulted primarily from exchange rate gains from operations of € 2.7 million (H1 2020: € 9.7 million).

Finance income amounted to € 116.3 million in the first six months of 2021 (H1 2020: € 28.1 million) and resulted in a total of € 108.3 million (H1 2020: € 22.3 million) from the net effects of the measurement of financial assets and liabilities from collaborations. This included effects from the differences between actual figures and planning assumptions, currency translation of the financial assets and fair value measurement of the financial assets. Also included is finance income from the investment of cash and investments and related foreign currency translation gains of € 8.0 million (H1 2020: € 5.8 million).

Finance expenses amounted to € 36.8 million in the first six months of 2021 (H1 2020: € 34.4 million) and resulted mainly from the effect of financial liabilities from collaborations in the amount of € 27.5 million (H1 2020: € 17.6 million) and, specifically from the application of the effective interest method and foreign currency valuation. Also included are finance expenses from the investment of cash and investments and related foreign currency translation losses of € 2.7 million (H1 2020: € 9.0 million). Furthermore, interest expenses were recognized in the amount of € 5.9 million from the convertible bond (H1 2020: € 0 million).

Income Taxes

The Group recognized total tax benefits of € 1.0 million in the first six months of 2021 (H1 2020: € 23.3 million). This amount consisted mainly of deferred tax expenses of € 13.5 million (H1 2020: deferred tax benefit € 132.1 million) on temporary differences and of € 14.7 million (H1 2020: € 0 million) relating to the recognition of deferred taxes on current period losses. Deferred taxes on temporary differences and loss carryforwards were capitalized in full due to the positive medium- to long-term business expectations for MorphoSys AG and MorphoSys US Inc. This assessment has not changed after the completion of the Constellation acquisition and the strategic financing partnership with Royalty Pharma.

Financial Position

Cash and Investments

On June 30, 2021, the Company had cash and investments, previously referred to as liquidity, of € 1,129.2 million, compared with € 1,244.0 million at December 31, 2020. The decrease in cash and investments resulted mainly from the use of cash for operating activities in the first six months of 2021.

Cash and investments are the sum of the balance sheet items "Cash and cash equivalents," "Financial assets at fair value through profit or loss," and current and non-current "Other financial assets at amortized cost."

Balance Sheet

Assets

Total assets on June 30, 2021 amounted to € 1,577.4 million, a decrease of € 82.1 million compared to December 31, 2020 (€ 1,659.5 million).

The increase in current assets resulted mainly from the increase in the balance sheet item "Cash and Cash Equivalents" by € 187.5 million and from the increase in the item "Other financial assets at amortized cost" by € 73.5 million, mainly due to a shift in the composition of the investments. Furthermore, "Accounts Receivable" increased by € 13.8 million and "Prepaid Expenses and Other Current Assets" by € 17.2 million. This increase was partially offset by a decrease in the item "Financial Assets at Fair Value through Profit or Loss" in the amount of € 234.7 million.

In comparison to December 31, 2020, non-current assets decreased by € 131.2 million to € 321.5 million, mainly due to the decrease in the balance sheet item "Other financial assets at amortized cost, net of current portion" by € 141.2 million as a result of a shift in the composition of the investments. This decrease was partially offset by an increase in the item "In-process R&D Programs" of € 10.4 million.

Liabilities

Current liabilities increased from € 200.5 million as of December 31, 2020 to € 204.6 million as of June 30, 2021, mainly as a result of a € 6.1 million increase in the item "Accounts payable and accruals". This increase was partly offset by a decrease of € 1.8 million in the balance sheet item "Current portion of contract liabilities".

Non-current liabilities decreased by € 66.3 million compared to December 31, 2020, mainly due to the decrease of the item "Financial liabilities from collaborations" in the amount of € 70.5 million due to adjustments in planning assumptions. This was partially offset by the increase of the item "Convertible Bond, Net of Current Portion" by € 4.9 million.

Stockholder's Equity

As of June 30, 2021, the Company's common stock including treasury shares amounted to € 32,892,540 (December 31, 2020: € 32,890,046). Common stock increased by € 2,494 and 2,494 shares, as a result of the exercise of 2,494 stock options granted to the Management Board and certain employees of the Company (beneficiaries) under the 2017 Stock Option Plan (SOP Plan). The vesting period for this stock option plan expired on April 1, 2021 and offers beneficiaries a three-year period until March 31, 2024 to receive a total of 79,935 shares. The exercise price amounted to € 55.52.

As of June 30, 2021, the value of treasury shares decreased from € 4,868,744 on December 31, 2020 to € 3,783,044. The reason for this decrease was the transfer of 27,786 treasury shares from the 2017 performance-based Long-Term Incentive Plan (LTI Plan) in the amount of € 1,026,971 to the Management Board and certain employees of the Company (beneficiaries). The vesting period for this LTI Plan expired on April 1, 2021 and offers beneficiaries a six-month period until October 13, 2021 to receive a total of 45,891 shares. In addition, 1,589 treasury shares in the amount of € 58,729 from the 2019 Long-Term Incentive Plan were transferred to certain employees of MorphoSys US Inc. As a result, the number of MorphoSys shares held by the Company as of June 30, 2021, amounted to 102,039 shares (December 31, 2020: 131,414 shares).

As of June 30, 2021, additional paid-in capital amounted to € 749,283,869 (December 31, 2020: € 748,978,506). The increase totaling € 305,363 was largely a result of the allocation of personnel expenses from share-based payments in the amount of € 1,276,490 and the exercise of stock options in the amount of € 114,573 net of transaction costs of € 21,400. Part of the increase was offset by a decline that resulted from the reclassification of treasury shares related to share allocations from the 2017 Long-Term Incentive Plan in the amount of € 1,026,971 as well as from the allocation of treasury shares from the 2019 LTI Plan of MorphoSys US Inc. to selected employees of MorphoSys US Inc. in the amount of € 58,729.

Risks and Opportunities

Through the acquisition of Constellation on July 15, 2021 and the related strategic financing partnership with Royalty Pharma, the risks and opportunities profile of MorphoSys Group changes compared to the situation described on pages 92-101 of the Annual Report 2020. The MorphoSys Group generally conducts a "risk run" twice a year, during which risks and opportunities are identified, updated and evaluated according to the defined internal processes, and appropriate countermeasures are discussed and, if necessary, initiated at the Management Board and Supervisory Board level. The effects of the transactions described are fully taken into account in the "risk run" of the second half of the year. The risks presented below therefore only address the material risks and opportunities in connection with the above transactions that were identified by the Management Board.

A detailed report on the risk and opportunity profile of MorphoSys Group, taking into account the Constellation acquisition, will therefore be provided in the Annual Report 2021.

A moderate operational risk is to ensure the progress of the development plan of Constellation's compounds in an advanced study phase. Constellation employees have specific program knowledge as it pertains to

clinical development, clinical data analysis, and other areas. In order to minimize any continuity risks, employees in key positions in the area of clinical development at Constellation were offered appropriate incentives to continue their employment.

In addition, a short-term moderate organizational risk has been identified which relates to the operational integration of Constellation into the MorphoSys Group. If MorphoSys does not succeed in integrating the acquired company into the Group structures and processes within a reasonable period of time, there is a risk that synergy potentials cannot be achieved as planned. As a risk-reducing measure, a project team consisting of experienced employees from Constellation and MorphoSys from different functions and departments has been set up to work on key aspects of the integration in different working groups.

The strategic financing partnership with Royalty Pharma provides MorphoSys with access to capital to finance the Constellation acquisition and also enhances future liquidity for research and development activities through milestone payments or access to a development funding bond.

Due to the high expected clinical development expenses and the associated liquidity requirements for the key development programs of the Constellation as well as MorphoSys compounds, a corresponding comprehensive liquidity planning was prepared, in which, among other things, the effects of different scenarios were simulated. As a measure to reduce the low financing risk, the findings of the liquidity planning are taken into account by the Management Board when prioritizing research and development projects and determining the financing requirements and the thereof resulting concrete financing activities.

In addition to the aforementioned risks, the expansion of the clinical development pipeline and possible synergies in the area of research and development as well as general administrative expenses offer potential opportunities to increase the value of the company.

The accounting treatment of the payment received by MorphoSys AG from Royalty Pharma in the third quarter of 2021 under German tax law could be challenged by the tax authorities in the context of a future tax audit which would be considered routine given the size of the payment. Based on the Company's knowledge of the German tax law which is further informed by experts in German tax law, the Company believes it is very probable that there will not be a different tax assessment. In the event of a different tax assessment, significant effects in the form of additional tax interest payments as well as an advance of the cash outflow from income taxes would have to be expected.

By letter dated June 10, 2021, MorphoSys was notified by a licensor of the initiation of arbitration proceedings in the United States. The licensor alleges breach of contract and claims damages for the licensor's argued loss of revenues. Despite the patent expiry in 2018 confirmed by the licensor at the time, this is now disputed and a significantly longer patent term is assumed. Taking into account the associated legal and consulting costs, the potential amount in dispute in the proceedings is in the low double-digit million range and also includes a currently unspecified share of royalty income. A decision by the arbitration court is expected in mid-2022. Based on the current assessment of the facts, MorphoSys believes that the arguments presented are unfounded and that the arbitration will likely be decided in MorphoSys's favor.

Outlook

Financial Guidance

MorphoSys updated its financial guidance for the 2021 financial year on July 26, 2021. The Group expects Group revenues in the range of € 155 million to € 180 million for the 2021 financial year compared to the prior guidance range of € 150 million to € 200 million. This guidance was narrowed primarily due to Monjuvi[®] product sales in the U.S. in the first six months of 2021 and expectations for the remaining months of 2021. The updated guidance excludes any royalties from the potential approval of tafasitamab outside of the U.S. as well as significant milestones from development partners and/or licensing partnerships other than those that were already recorded in the first six months of 2021. The guidance is subject to a number of uncertainties, including potential fluctuations in the first full year of Monjuvi[®]'s launch, the limited visibility MorphoSys has with respect to the Tremfya royalties, as well as the ongoing COVID-19 pandemic and the related impact on our business as well as that of our partners.

MorphoSys expects Group operating expenses, which are comprised of research and development, selling as well as general and administrative expenses, in the range of € 435 million to € 465 million (previously € 355 million to € 385 million), which include expenses for Constellation starting July 15, 2021. The revised Group operating expenses range also include one-time transaction related costs of € 36 million related to the agreements with Constellation and Royalty Pharma. Research and development expenses now are expected to comprise 52% to 57% of Group operating expenses (previously 45% to 50%), excluding the one-time transaction-related costs.

The statements in the 2020 Annual Report on pages 88-91 concerning the strategic outlook, the expected business and human resource developments, future research and development, and the dividend policy continue to apply.

Consolidated Statement of Profit or Loss (IFRS) – (unaudited)

in €	Note	Q2 2021 ¹	Q2 2020 ^{1,2}	H1 2021	H1 2020 ²
Revenues	2	38,233,992	18,434,036	85,423,609	269,656,727
Cost of Sales		(10,136,312)	7,227,804	(15,184,293)	3,968,326
Gross Profit	1	28,097,680	25,661,840	70,239,316	273,625,053
Operating Expenses					
Research and Development		(40,506,812)	(30,932,839)	(73,823,916)	(52,428,972)
Selling		(28,461,138)	(29,278,842)	(56,627,048)	(42,106,431)
General and Administrative		(30,493,263)	(13,816,895)	(40,751,085)	(23,940,517)
Total Operating Expenses	1	(99,461,213)	(74,028,576)	(171,202,049)	(118,475,920)
Operating Profit / (Loss)	1	(71,363,533)	(48,366,736)	(100,962,733)	155,149,133
Other Income		1,663,390	(360,300)	2,838,468	9,969,474
Other Expenses		(1,437,088)	(1,344,435)	(3,409,133)	(1,629,971)
Finance Income		102,411,620	17,470,786	116,308,866	28,071,456
Finance Expenses		2,926,302	(25,076,101)	(36,763,703)	(34,363,514)
Income from Reversals of Impairment Losses / (Impairment Losses) on Financial Assets		196,000	(311,000)	285,000	(772,000)
Income Tax Benefit / (Expenses)	3	(13,502,482)	4,899,051	989,211	23,336,280
Consolidated Net Profit / (Loss)		20,894,209	(53,088,735)	(20,714,024)	179,760,858
Earnings per Share, Basic and Diluted		-	(1.62)	(0.63)	-
Earnings per Share, Basic		0.64	-	-	5.56
Earnings per Share, diluted		0.61	-	-	5.54
Shares Used in Computing Earnings per Share, Basic and Diluted		-	32,696,980	32,772,125	-
Shares Used in Computing Earnings per Share, Basic		32,781,475	-	-	32,309,894
Shares Used in Computing Earnings per Share, Diluted		35,371,193	-	-	32,437,297

¹ The three month period is not part of the auditor's review.

² The consolidated statement of profit or loss has been adjusted to present comparable information for the previous year. For details we refer to the section "Structural Changes to the Consolidated Statement of Profit or Loss" in section 1 of the notes.

Consolidated Statement of Comprehensive Income (IFRS) – (unaudited)

in €	Q2 2021 ¹	Q2 2020 ¹	H1 2021	H1 2020
Consolidated Net Profit / (Loss)	20,894,209	(53,088,735)	(20,714,024)	179,760,858
Items that will not be reclassified to Profit or Loss				
Change in Fair Value of Shares through Other Comprehensive Income	0	(303,371)	0	(3,565,402)
Items that may be reclassified to Profit or Loss				
Foreign Currency Translation Differences from Consolidation	333,222	1,329,973	(594,594)	580,257
Other Comprehensive Income	333,222	1,026,602	(594,594)	(2,985,145)
Total Comprehensive Income	21,227,431	(52,062,133)	(21,308,618)	176,775,713

¹ The three month period is not part of the auditor's review.

Consolidated Balance Sheet (IFRS) – (unaudited)

in €	Note	06/30/2021	12/31/2020
ASSETS			
Current Assets			
Cash and Cash Equivalents	4	297,334,811	109,794,680
Financial Assets at Fair Value through Profit or Loss	4	53,255,377	287,937,972
Other Financial Assets at Amortized Cost	4	723,257,031	649,713,342
Accounts Receivable	4	97,166,501	83,354,276
Financial Assets from Collaborations	4	21,497,150	42,870,499
Income Tax Receivables		504,364	401,826
Other Receivables		10,521,549	2,159,475
Inventories, Net		14,517,118	9,962,657
Prepaid Expenses and Other Current Assets		37,853,108	20,621,493
Total Current Assets		1,255,907,009	1,206,816,220
Non-current Assets			
Property, Plant and Equipment, Net		6,269,951	6,323,753
Right-of-Use Assets, Net		43,153,949	44,417,767
Patents, Net		1,963,968	1,937,856
Licenses, Net		11,342,467	11,835,619
Licenses for Marketed Products		54,329,930	55,485,886
In-process R&D Programs		10,428,750	0
Internally Generated Intangible Assets		829,300	0
Software, Net		130,908	115,788
Goodwill		1,619,233	1,619,233
Other Financial Assets at Amortized Cost, Net of Current Portion	4	55,378,227	196,587,542
Deferred Tax Asset	3	134,290,594	132,806,097
Prepaid Expenses and Other Assets, Net of Current Portion	4	1,770,095	1,567,259
Total Non-current Assets		321,507,372	452,696,800
Total Assets		1,577,414,381	1,659,513,020

in €	Note	06/30/2021	12/31/2020
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current Liabilities			
Accounts Payable and Accruals	4	134,663,434	128,554,203
Current Portion of Lease Liabilities	4	3,264,506	3,055,608
Tax Liabilities	3	64,768,479	65,727,675
Other Provisions		658,150	0
Current Portion of Contract Liability		781,925	2,543,903
Current Portion of Convertible Bond		417,282	422,945
Current Portion of Financial Liabilities from Collaborations	4, 5	0	154,895
Total Current Liabilities		204,553,776	200,459,229
Non-current Liabilities			
Lease Liabilities, Net of Current Portion	4	40,593,526	41,963,794
Other Provisions, Net of Current Portion		2,219,544	1,527,756
Contract Liability, Net of Current Portion		50,280	71,829
Deferred Tax Liability	3	5,057,465	5,057,465
Convertible Bond, Net of Current Portion		277,676,710	272,759,970
Financial Liabilities from Collaborations, Net of Current Portion	4, 5	445,856,124	516,350,960
Total Non-current Liabilities		771,453,649	837,731,774
Total Liabilities		976,007,425	1,038,191,003
Stockholders' Equity			
Common Stock	6	32,892,540	32,890,046
Ordinary Shares Issued (32,892,540 and 32,890,046 for 2021 and 2020, respectively)			
Ordinary Shares Outstanding (32,790,501 and 32,758,632 for 2021 and 2020, respectively)			
Treasury Stock (102,039 and 131,414 shares for 2021 and 2020, respectively), at Cost		(3,783,044)	(4,868,744)
Additional Paid-in Capital	6	749,283,869	748,978,506
Other Comprehensive Income Reserve	6	1,616,825	2,211,419
Accumulated Deficit		(178,603,234)	(157,889,210)
Total Stockholders' Equity		601,406,956	621,322,017
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		1,577,414,381	1,659,513,020

Consolidated Statement of Changes in Stockholders' Equity (IFRS) – (unaudited)

	Common Stock	
	Shares	€
Balance as of January 1, 2020	31,957,958	31,957,958
Capital Increase, Net of Issuance Cost of € 100,370	907,441	907,441
Compensation Related to the Grant of Stock Options and Performance Shares	0	0
Exercise of Convertible Bonds Issued	24,647	24,647
Transfer of Treasury Stock for Long-Term Incentive Programs	0	0
Reserves:		
Change in Fair Value of Shares through Other Comprehensive Income	0	0
Foreign Currency Translation Differences from Consolidation	0	0
Consolidated Net Profit	0	0
Total Comprehensive Income	0	0
Balance as of June 30, 2020	32,890,046	32,890,046
Balance as of January 1, 2021	32,890,046	32,890,046
Compensation Related to the Grant of Stock Options and Performance Shares	6, 10	0
Exercise of Stock Options Issued	6, 7, 11	2,494
Transfer of Treasury Stock for Long-Term Incentive Programs	6, 7, 11	0
Reserves:		
Foreign Currency Translation Differences from Consolidation	0	0
Consolidated Net Loss	0	0
Total Comprehensive Income	0	0
Balance as of June 30, 2021	32,892,540	32,892,540

Treasury Stock		Additional Paid-in Capital	Other Comprehensive Income Reserve	Accumulated Deficit	Total Stockholders' Equity
Shares	€				
225,800	(8,357,250)	628,176,568	(1,295,718)	(255,779,786)	394,701,772
0	0	79,590,657	0	0	80,498,098
0	0	3,751,660	0	0	3,751,660
0	0	760,976	0	0	785,623
(53,392)	1,973,368	(1,973,368)	0	0	0
0	0	0	(3,565,402)	0	(3,565,402)
0	0	0	580,257	0	580,257
0	0	0	0	179,760,858	179,760,858
0	0	0	(2,985,145)	179,760,858	176,775,713
172,408	(6,383,882)	710,306,493	(4,280,863)	(76,018,928)	656,512,866
131,414	(4,868,744)	748,978,506	2,211,419	(157,889,210)	621,322,017
0	0	1,276,490	0	0	1,276,490
0	0	114,573	0	0	117,067
(29,375)	1,085,700	(1,085,700)	0	0	0
0	0	0	(594,594)	0	(594,594)
0	0	0	0	(20,714,024)	(20,714,024)
0	0	0	(594,594)	(20,714,024)	(21,308,618)
102,039	(3,783,044)	749,283,869	1,616,825	(178,603,234)	601,406,956

Consolidated Statement of Cash Flows (IFRS) – (unaudited)

H1 (in €)	Note	2021	2020
Operating Activities:			
Consolidated Net Profit / (Loss)		(20,714,024)	179,760,858
Adjustments to Reconcile Consolidated Net Profit / (Loss) to Net Cash Provided by / (Used in) Operating Activities:			
Impairments of Assets		116,001	14,305,306
Depreciation and Amortization of Tangible and Intangible Assets and of Right-of-Use Assets		4,654,051	3,696,928
Net (Gain) / Loss of Financial Assets at Fair Value through Profit or Loss		(615,851)	1,226,920
Net (Gain) / Loss of Financial Assets at Amortized Cost		(1,868,504)	2,751,558
(Income) from Reversals of Impairments / Impairments on Financial Assets		(285,000)	772,000
Net (Gain) / Loss on Derivative Financial Instruments		0	6,991,506
Non Cash Effective Net Change in Financial Assets / Liabilities from Collaborations		(80,796,823)	(4,642,257)
Non Cash Effective Change of Financial Liabilities at Amortized Cost		5,926,887	0
(Income) from Reversals of Impairments on Inventories		0	(15,509,559)
Recognition of Contract Liability		(2,385,710)	(7,987,408)
Share-based Payment	10	1,854,488	4,395,357
Income Tax (Benefit) / Expenses	3	(989,211)	(23,336,280)
Changes in Operating Assets and Liabilities:			
Accounts Receivable		(13,154,588)	(18,021,317)
Inventories, Prepaid Expenses and Other Assets, Tax Receivables and Other Receivables		(29,647,859)	(3,980,369)
Accounts Payable and Accruals, Lease Liabilities, Tax Liabilities and Other Provisions		5,802,027	(2,124,194)
Other Liabilities		0	118,489
Contract Liability		602,182	11,389,563
Income Taxes Paid		(83,363)	(45,156)
Net Cash Provided by / (Used in) Operating Activities		(131,585,297)	149,761,945

H1 (in €)	Note	2021	2020
Investing Activities:			
Cash Payments to Acquire Financial Assets at Fair Value through Profit or Loss		0	(416,449,668)
Cash Receipts from Sales of Financial Assets at Fair Value through Profit or Loss		235,645,206	41,521,507
Cash Payments to Acquire Other Financial Assets at Amortized Cost		(786,452,089)	(476,140,326)
Cash Receipts from Sales of Other Financial Assets at Amortized Cost		855,799,950	131,190,000
Cash Receipts from (+) / Cash Payments for (-) Derivative Financial Instruments		0	(6,595,240)
Cash Payments to Acquire Property, Plant and Equipment		(971,053)	(1,504,428)
Cash Payments to Acquire Intangible Assets and for Internally Generated Intangible Assets		(11,449,733)	(11,544,656)
Cash Receipts from Sales of Shares at Fair Value through Other Comprehensive Income		0	1,103,433
Interest Received		155,459	166,591
Net Cash Provided by / (Used in) Investing Activities		292,727,740	(738,252,787)
Financing Activities:			
Cash Proceeds from Issuing Shares		0	80,598,468
Cash Payments for Costs from Issuing Shares	6	(21,400)	(100,370)
Cash Proceeds in Connection with Stock Options (2021) and Convertible Bonds (2020)	6	138,467	773,300
Cash Receipts from Financing from Collaborations		31,520,343	497,509,605
Cash Payments for Principal Elements of Lease Payments		(1,560,976)	(1,233,706)
Interest Paid		(2,219,439)	(683,835)
Net Cash Provided by / (Used in) Financing Activities		27,856,995	576,863,462
Effect of Exchange Rate Differences on Cash		(1,459,307)	717,681
Increase / (Decrease) in Cash and Cash Equivalents		187,540,131	(10,909,699)
Cash and Cash Equivalents at the Beginning of the Period		109,794,680	44,314,050
Cash and Cash Equivalents at the End of the Period		297,334,811	33,404,351

Notes to the Consolidated Financial Statements (unaudited)

MorphoSys AG ("the Company" or "MorphoSys") is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The Company has a proprietary portfolio of compounds and a pipeline of compounds developed with partners from the pharmaceutical and biotechnology industry. MorphoSys was founded as a German limited liability company in July 1992. In June 1998, MorphoSys became a German stock corporation. In March 1999, the Company completed its initial public offering on Germany's "Neuer Markt": the segment of the Deutsche Börse designated, at that time, for high-growth companies. On January 15, 2003, MorphoSys AG was admitted to the Prime Standard segment of the Frankfurt Stock Exchange. On April 18, 2018, MorphoSys completed an IPO on the Nasdaq Global Market through the issue of American Depositary Shares (ADS). Each ADS represents 1/4 of a MorphoSys ordinary share. MorphoSys AG's registered office is located in Planegg (district of Munich), and the registered business address is Semmelweisstrasse 7, 82152 Planegg, Germany. The MorphoSys AG consolidated and separate financial statements can be viewed at this address. The Company is registered in the Commercial Register B of the District Court of Munich under the number HRB 121023.

These interim consolidated financial statements were prepared in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standards Board (IASB), taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (IFRS IC) as applicable in the European Union (EU). These interim consolidated financial statements comply with IAS 34 "Interim Financial Reporting."

The condensed interim consolidated financial statements do not contain all of the information and disclosures required for the financial year-end consolidated financial statements and therefore should be read in conjunction with the consolidated financial statements dated December 31, 2020.

The condensed interim consolidated financial statements were approved for publication on July 27, 2021.

The consolidated financial statements as of June 30, 2021, include MorphoSys AG and MorphoSys US Inc. (Boston, Massachusetts, USA), which are collectively known as the "Group." MorphoSys Development Inc. (Dover, Delaware, U.S.) was established as a wholly owned subsidiary of MorphoSys US Inc. on May 28, 2021. MorphoSys Development Inc., therefore, is a wholly owned indirect investment of MorphoSys AG. For reasons of materiality, MorphoSys Development Inc. was not consolidated as of June 30, 2021.

1. Accounting Policies

Except for the principles described below, the accounting and valuation principles applied to the consolidated financial statements for the financial year ending December 31, 2020, were the same as those applied to the first six months of 2021. The consolidated financial statements as of December 31, 2020 are available on the Company's website at www.morphosys.com/media-and-investors/financial-information#reports.

Structural Changes to the Segment Reporting

As of the first quarter of 2021, MorphoSys no longer presents the previous segment information for the Proprietary Development and Partnered Discovery segments as part of the regular internal reporting to the Management Board as the Company's chief operating decision-maker. Internal reporting focuses exclusively on the key value drivers of future revenues from product sales, further market approvals for tafasitamab, and Group royalties. The previous segment reporting was published for the last time for external purposes as of December 31, 2020. Reporting now comprises only the consolidated statement of profit or loss and no longer includes separate segment reporting.

Structural Changes to the Consolidated Statement of Profit or Loss

The change in the Company's internal management and corresponding financial guidance for the 2021 financial year also prompted changes in the presentation of the consolidated statement of profit or loss. The following changes were implemented for the first time with the reporting on the first six months of 2021:

- Introduction of the item "Gross Profit" on the statement of profit or loss as the difference between revenues and cost of sales
- "Operating Expenses" include research and development, as well as selling, general and administrative expenses. In this context, total operating expenses for the first six months of 2020 were adjusted by € 4.0 million as the cost of sales are no longer included in this sum line item in order to provide comparable prior year information.
- The item "Earnings before Interest and Taxes" (EBIT) on the statement of profit or loss has been discontinued
- Introduction of the item "Operating Profit (+) / Loss (-)" on the statement of profit or loss as the difference between the statement's items "Gross Profit" and "Operating Expenses"

The prior year's presentation of the figures has been adjusted accordingly in order to provide comparable information for the previous year.

Other Business Transactions Relevant for Financial Reporting

Starting with the first quarter of 2021, certain development costs related to tafasitamab and Monjuvi[®] have been capitalized as internally generated intangible assets for the first time, as the recognition criteria as stated in MorphoSys' Annual Report 2020 in Section 2.8.8 are met. They are shown as the balance sheet item "Internally Generated Intangible Assets." The development of these assets is currently not yet completed and therefore they are not yet subject to amortization. Until the development activities are completed, the capitalized assets will undergo an annual impairment test.

New and Revised Standards Applied for the First Time in the Financial Year

The impact on the consolidated financial statements from the amendment to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 is not considered to be material and are therefore not explained separately. Standards with the remark "none" do not have a material impact on the consolidated financial statements.

Standard/Interpretation		Mandatory Application for financial years starting on	Adopted by the European Union	Possible Impact on MorphoSys
IFRS 4 (A)	Deferral of IFRS 9	01/01/2021	yes	none
IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (A)	Interest Rate Benchmark Reform - Phase 2	01/01/2021	yes	yes
(A) Amendments				

New and Revised Standards not yet Mandatory

The following new and revised standards that were not yet mandatory in the reporting period or not yet adopted by the European Union were not applied in advance. Standards with the remark "yes" are likely to have an impact on the consolidated financial statements and are currently being assessed by the Group. The following discussion focuses only on those changes that have a material impact. The impact on the consolidated financial statements from the amendments to IAS 1, IAS 8 and IAS 12 are not considered to be material and are therefore not explained separately. Standards with the remark "none" are not expected to have a material impact on the consolidated financial statements.

Standard/Interpretation		Mandatory Application for financial years starting on	Adopted by the European Union	Possible Impact on MorphoSys
IFRS 3 (A)	Reference to the Conceptual Framework	01/01/2022	yes	none
IFRS 16 (A)	COVID-19 Related Rent Concessions beyond June 30, 2021	04/01/2021	no	none
IFRS 17 und IFRS 17 (A)	Insurance Contracts including Amendments to IFRS 17	01/01/2023	no	none
IAS 1 (A)	Classification of Liabilities as Current or Non-current	01/01/2023	no	yes
IAS 1 (A)	Disclosure of Accounting Policies	01/01/2023	no	yes
IAS 8 (A)	Definition of Accounting Estimates	01/01/2023	no	yes
IAS 12 (A)	Deferred Tax related to Assets and Liabilities arising from a Single Transaction	01/01/2023	no	yes
IAS 16 (A)	Property, Plant and Equipment – Proceeds before Intended Use	01/01/2022	yes	none
IAS 37 (A)	Onerous Contracts – Cost of Fulfilling a Contract	01/01/2022	yes	none
Annual Improvements to International Financial Reporting Standards, 2018 - 2020		01/01/2022	yes	none
(A) Amendments				

2. Revenues

The table below provides an overview of the geographic distribution of Group revenues based on the location of product sales or our customers' headquarters.

in 000' €	2021	2020
Germany	0	0
Europe and Asia	20,443	3,675
USA and Canada	64,981	265,982
Total	85,424	269,657

Group revenue included milestone payments in the amount of € 17.7 million (H1 2020: € 2.9 million) as well as royalties totaling € 25.4 million (H1 2020: € 20.1 million). Of total group revenues, € 53.2 million were generated from three customers (H1 2020: one customer amounting to € 243.6 million), which each accounted for more than 10% of total revenues.

The following overview shows the point in time the performance obligations were met.

in 000' €	2021	2020
At a Point in Time thereof performance obligations fulfilled in previous periods: € 43.1 million in 2021, € 22.9 million in 2020	85,402	269,490
Over Time	22	167
Total	85,424	269,657

3. Income Taxes

The Group recognized total tax benefits of € 1.0 million in the first six months of 2021 (H1 2020: € 23.3 million). This amount consisted mainly of deferred tax expenses of € 13.5 million (H1 2020: deferred tax benefit € 132.1 million) on temporary differences and of € 14.7 million (H1 2020: € 0 million) relating to the recognition of deferred taxes on current period losses, as well as current tax expenses of € 0.2 million (H1 2020: € 108.8 million). The current tax expense consists of income taxes for the current period in the amount of € 1.0 million and, offsetting, € 0.8 million for a loss carryback for corporation tax.

4. Fair Value Measurement

MorphoSys uses the hierarchy below for determining and disclosing the fair value of financial instruments.

Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities to which the Company has access.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (i.e., unobservable inputs).

The carrying amounts of certain financial assets and liabilities, such as for example other financial assets at amortized cost, as well as accounts payable and receivable, approximate their fair values due to their short-term maturities.

Hierarchy Level 2 contains foreign exchange forward agreements to hedge exchange rate fluctuations, term deposits, restricted cash and convertible bonds. Future cash flows for these foreign exchange forward agreements are determined based on forward exchange rate curves. The fair value of these instruments corresponds to their discounted cash flows. The fair value of the term deposits and restricted cash is determined by discounting the expected cash flows with risk-adjusted and maturity-appropriate market interest rates. The fair value of the convertible bonds was determined by calculating the present value of all cash flows associated with the liability using the applicable reference interest rate with an adjustment to reflect MorphoSys' credit risk premium.

Hierarchy Level 3 financial assets comprise investments at fair value through other comprehensive income, as well as financial assets and financial liabilities from collaborations. The underlying valuations are generally carried out by employees in the finance department who report directly to the Chief Financial Officer. The valuation process and results are reviewed and discussed among the persons involved on a regular basis. The financial assets from collaborations represent MorphoSys' current reimbursement claim against Incyte from the expected future losses associated with the co-commercialization activities of Monjuvi[®] as second-line treatment for relapsed or refractory diffuse large B-cell lymphoma ("DLBCL") in the U.S. (as Incyte has agreed to compensate MorphoSys for 50% of said losses). To determine the fair value of financial assets from collaborations, expected cash inflows are discounted using market interest rates of financial instruments with comparable currencies and maturities, taking into account Incyte's credit risk. The non-current financial liabilities from collaborations represent Incyte's entitlement against MorphoSys to future profit sharing on sales of Monjuvi[®] as second-line treatment for DLBCL in the U.S. (as MorphoSys will share 50% of these profits with Incyte). In order to determine the fair value of the non-current financial liabilities from collaborations for disclosure purposes (these are accounted for at amortized cost using the effective interest method), expected cash outflows are discounted using market interest rates of financial instruments with comparable currencies and maturities, taking into account the credit risk of MorphoSys. The cash inflows and outflows represent estimates of future revenues and costs from the co-promotion activities of Monjuvi[®] as second-line treatment for DLBCL in the U.S. and are subject to significant discretion. These estimates are based on assumptions that are jointly arrived at and approved of twice each year by the responsible departments at MorphoSys and Incyte. Financial assets and financial liabilities from collaborations are furthermore subject to significant uncertainties from currency exchange rate developments. Further details on the collaboration and license

agreement with Incyte can be found in section 4 of the notes to the consolidated financial statements as of December 31, 2020.

Principally, reclassifications between the different fair value hierarchy levels are recognized as of the reporting dates, but neither in 2020 nor in 2021 such transfers took place.

The fair values of financial assets and liabilities and the carrying amounts presented in the consolidated balance sheet consist of the following items:

June 30, 2021; in 000' €	Hierarchy Level	Not classified into a Measurement Category	Financial Assets at Amortized Cost	Financial Assets at Fair Value (Through Profit or Loss)
Cash and Cash Equivalents	*	0	297,335	0
Financial Assets at Fair Value through Profit or Loss	1	0	0	53,255
Other Financial Assets at Amortized Cost	*	0	723,257	0
Accounts Receivable	*	0	97,167	0
Financial Assets from Collaborations	3	0	0	21,497
Other Receivables	*	0	10,522	0
Current Financial Assets		0	1,128,281	74,752
Other Financial Assets at Amortized Cost, Net of Current Portion	1	0	55,378	0
Prepaid Expenses and Other Assets, Net of Current Portion				
thereof Non-Financial Assets	n/a	273	0	0
thereof Restricted Cash	2	0	1,497	0
Non-current Financial Assets		273	56,875	0
Total		273	1,185,156	74,752
Accounts Payable and Accruals	*	0	0	0
Current Portion of Lease Liabilities	n/a	(3,265)	0	0
Current Portion of Convertible Bond	*	0	0	0
Current Financial Liabilities		(3,265)	0	0
Lease Liabilities, Net of Current Portion	n/a	(40,594)	0	0
Convertible Bond, Net of Current Portion	2	0	0	0
Financial Liabilities from Collaborations, Net of Current Portion	3	0	0	0
Non-current Financial Liabilities		(40,594)	0	0
Total		(43,859)	0	0

	Financial Assets at Fair Value (Through Other Comprehensive Income)	Financial Liabilities at Amortized Cost	Financial Liabilities at Fair Value	Total Carrying Amount	Fair value
	0	0	0	297,335	*
	0	0	0	53,255	53,255
	0	0	0	723,257	*
	0	0	0	97,167	*
	0	0	0	21,497	21,497
	0	0	0	10,522	*
	0	0	0	1,203,033	
	0	0	0	55,378	55,787
				1,770	
	0	0	0	273	n/a
	0	0	0	1,497	1,497
	0	0	0	57,148	
	0	0	0	1,260,181	
	0	(134,663)	0	(134,663)	*
	0	0	0	(3,265)	**
	0	(417)	0	(417)	*
	0	(135,080)	0	(138,345)	
	0	0	0	(40,594)	**
	0	(277,677)	0	(277,677)	(315,869)
	0	(445,856)	0	(445,856)	(516,357)
	0	(723,533)	0	(764,127)	
	0	(858,613)	0	(902,472)	

* Declaration waived in line with IFRS 7.29 (a). For these instruments the carrying amount is a reasonable approximation of fair value

** Declaration waived in line with IFRS 7.29 (d) as disclosure is not required for lease liabilities.

December 31, 2020; in 000' €	Hierarchy Level	Not classified into a Measurement Category	Financial Assets at Amortized Cost	Financial Assets at Fair Value (Through Profit or Loss)
Cash and Cash Equivalents	*	0	109,795	0
Financial Assets at Fair Value through Profit or Loss	1	0	0	287,938
Other Financial Assets at Amortized Cost	*	0	649,713	0
Accounts Receivable	*	0	83,354	0
Financial Assets from Collaborations	3	0	0	42,870
Other Receivables	*	0	2,159	0
Current Financial Assets		0	845,021	330,808
Other Financial Assets at Amortized Cost, Net of Current Portion	1	0	196,588	0
Prepaid Expenses and Other Assets, Net of Current Portion				
thereof Non-Financial Assets	n/a	183	0	0
thereof Restricted Cash	2	0	1,384	0
Non-current Financial Assets		183	197,972	0
Total		183	1,042,993	330,808
Accounts Payable and Accruals	*	0	0	0
Current Portion of Lease Liabilities	n/a	(3,056)	0	0
Current Portion of Convertible Bond	*	0	0	0
Current Portion of Financial Liabilities from Collaborations	*	0	0	0
Current Financial Liabilities		(3,056)	0	0
Lease Liabilities, Net of Current Portion	n/a	(41,964)	0	0
Convertible Bond, Net of Current Portion	2	0	0	0
Financial Liabilities from Collaborations, Net of Current Portion	3	0	0	0
Non-current Financial Liabilities		(41,964)	0	0
Total		(45,020)	0	0

	Financial Assets at Fair Value (Through Other Comprehensive Income)	Financial Liabilities at Amortized Cost	Financial Liabilities at Fair Value	Total Carrying Amount	Fair value
	0	0	0	109,795	*
	0	0	0	287,938	287,938
	0	0	0	649,713	*
	0	0	0	83,354	*
	0	0	0	42,870	42,870
				2,159	*
	0	0	0	1,175,829	
	0	0	0	196,588	197,749
				1,567	
	0	0	0	183	n/a
	0	0	0	1,384	1,384
	0	0	0	198,155	
	0	0	0	1,373,985	
	0	(128,554)	0	(128,554)	*
	0	0	0	(3,056)	**
	0	(423)	0	(423)	*
	0	(155)	0	(155)	*
	0	(129,132)	0	(132,188)	
	0	0	0	(41,964)	**
	0	(272,760)	0	(272,760)	(334,124)
	0	(516,351)	0	(516,351)	(617,178)
	0	(789,111)	0	(831,075)	
	0	(918,243)	0	(963,263)	

* Declaration waived in line with IFRS 7.29 (a). For these instruments the carrying amount is a reasonable approximation of fair value.

** Declaration waived in line with IFRS 7.29 (d) as disclosure is not required for lease liabilities.

As of June 30, 2021, the fair value of the investment in adivo GmbH continued to be measured at € 0 (December 31, 2020: € 0).

In the first half-years of 2021 and 2020, financial assets from collaborations that are valued according to Level 3 fair value developed as follows:

In T €	2021	2020
Balance as of January 1	42,870	0
Additions	0	45,090
Cash Receipts	(31,520)	0
Through Other Comprehensive Income	0	0
Through Profit or Loss (in Finance Result)	10,147	243
Balance as of June 30	21,497	45,332

If the expected revenues and cost components changed by 1%, the fair value of the financial assets from collaborations as of June 30, 2021 would be in a range of € 20.8 million to € 22.2 million.

5. Other Disclosures On Financial Instruments

The planning assumptions underlying the financial assets and liabilities from collaborations are influenced by significant estimates and mainly comprise revenues and costs for the production and selling expenses for Monjuvi® in the U.S., the discount rate, and the expected term of cash flows. Revenues are affected by variable influencing factors such as patient numbers and the number of doses of Monjuvi® administered, as well as the price that can be obtained in the market. Costs include the manufacturing costs for these doses of Monjuvi® and other cost components for the sale, transport, insurance and packaging, among others. The term is the estimated time period over which Monjuvi® will generate benefits in the approved indication and therefore the expected term of product sales in the U.S.

Compared with December 31, 2020, the planning assumptions regarding the expected net cash flows from the financial liabilities from collaborations have changed as of June 30, 2021. A total of € 98.1 million was recognized in profit or loss in the financial income. Changes resulted from lower expected future revenues, lower costs for the production and lower selling expenses for Monjuvi® in the U.S.

The estimates underlying the financial liabilities from collaborations are subject to a sensitivity analysis below. Based on this analysis, the following effects on the fair value of the financial liabilities from collaborations as of June 30, 2021 would have resulted. In each case, one planning assumption was changed, and all other estimates were kept constant.

in million €	+ 1%	[1]%
Change in Price obtained in the Market (revenue related)	8.7	(8.7)
Change in Patient Numbers and Number of Doses administered (revenue related)	7.8	(7.8)
Change in Manufacturing Costs and other Cost Components (cost related)	(4.3)	4.3
Change in Patient Numbers and Number of Doses administered (cost related)	(0.8)	0.8

6. Changes in Stockholders' Equity

Common stock

As of June 30, 2021, the Company's common stock including treasury shares amounted to € 32,892,540 (December 31, 2020: € 32,890,046). Common stock increased by € 2,494 and 2,494 shares, as a result of the exercise of 2,494 stock options granted to the Management Board and certain employees of the Company (beneficiaries) under the 2017 Stock Option Plan (SOP Plan). The vesting period for this stock option plan expired on April 1, 2021 and offers beneficiaries a three-year period until March 31, 2024 to receive a total of 79,935 shares. The exercise price amounted to € 55.52.

As of June 30, 2021, the value of treasury shares decreased from € 4,868,744 on December 31, 2020 to € 3,783,044. The reason for this decrease was the transfer of 27,786 treasury shares from the 2017 performance-based Long-Term Incentive Plan (LTI Plan) in the amount of € 1,026,971 to the Management Board and certain employees of the Company (beneficiaries). The vesting period for this LTI Plan expired on April 1, 2021 and offers beneficiaries a six-month period until October 13, 2021 to receive a total of 45,891 shares. In addition, 1,589 treasury shares in the amount of € 58,729 from the 2019 Long-Term Incentive Plan were transferred to certain employees of MorphoSys US Inc. As a result, the number of MorphoSys shares held by the Company as of June 30, 2021, amounted to 102,039 shares (December 31, 2020: 131,414 shares).

Additional Paid-in Capital

As of June 30, 2021, additional paid-in capital amounted to € 749,283,869 (December 31, 2020: € 748,978,506). The increase totaling € 305,363 was largely a result of the allocation of personnel expenses from share-based payments in the amount of € 1,276,490 and the exercise of stock options in the amount of € 114,573 net of transaction costs of € 21,400. Part of the increase was offset by a decline that resulted from the reclassification of treasury shares related to share allocations from the 2017 Long-Term Incentive Plan in the amount of € 1,026,971 as well as from the allocation of treasury shares from the 2019 LTI Plan of MorphoSys US Inc. to selected employees of MorphoSys US Inc. in the amount of € 58,729.

Other Comprehensive Income Reserve

On June 30, 2021, the other comprehensive income reserve contained changes in the fair value of equity instruments through other comprehensive income in the amount of € 0 (December 31, 2020: € 1,260,132) and foreign currency translation differences from consolidation of € -594,594 (December 31, 2020: € 2,247,005). The currency translation differences from consolidation include exchange rate differences from the revaluation of the financial statements of Group companies prepared in foreign currencies and differences between the exchange rates used in the balance sheet and income statement.

7. Development of Stock Options, Performance Share Units, Performance Shares and Convertible Bonds

In the first six months of 2021, there were no stock options and convertible bonds issued to the Management Board, Senior Management Group or employees.

In April 2021, 122,005 performance share units were issued under the 2021 Performance Share Unit Program (PSU Program) to the Management Board and certain Company employees. Further details can be found in Note 8.

In April 2021, 67,724 performance shares were granted under the MorphoSys US Inc. 2021 Restricted Stock Unit Plan (RSU Plan) to certain employees of MorphoSys US Inc. Further details can be found in Note 9.

After the expiration of the four-year vesting period, the Management Board and certain Company employees were granted a six-month period to receive a total of 45,891 shares under the 2017 LTI Plan. As of June 30, 2021, a total of 27,786 shares from the 2017 LTI Plan were transferred to the program's beneficiaries.

After the expiration of the four-year vesting period, the Management Board and certain Company employees were granted a three-year period to receive a total of 79,935 shares under the 2017 SOP Plan. As of June 30, 2021, a total of 2,494 shares from the 2017 SOP Plan were transferred to the program's beneficiaries.

After the end of the second one-year performance period, the President and certain employees of MorphoSys US Inc. were granted a six-month period to receive a total of 2,369 performance shares under the 2019 LTI Plan. As of June 30, 2021, a total of 1,589 shares from the 2019 LTI Plan were transferred to the program's beneficiaries.

8. Performance Share Unit Program

2020 Performance Share Unit Program

In March 2021, the terms of the Performance Share Unit Programs (PSU Programs) of April 1, 2020 and June 1, 2020 for the Management Board and certain employees of the Company (beneficiaries) were amended so that the number of Performance Share Units still to be vested for the remaining three years is calculated on the basis of the performance criteria of the absolute performance of the MorphoSys share price and the relative performance of the MorphoSys share price compared to the performance of the EURO STOXX Total Market Pharmaceuticals & Biotechnology Index. Previously, the number of performance share units earned in the first year was calculated on the basis of the performance criteria of the absolute and relative performance of the MorphoSys share price compared to the performance of the Nasdaq Biotech Index and the TecDAX Index. If the predefined performance criteria for the respective period are fully met, 25% of the performance share units become vested in the first year, and 75% become vested during the remaining three-year vesting period. The modification of the program's terms concerns the respective remaining vesting periods/performance periods of the programs for the subsequent three years as of April 1, 2021 and June 1, 2021. The approval of the Management Board and certain employees of the Company (beneficiaries) to the modified program terms was obtained by April 17, 2021. The modification of the programs had no material impact on the fair values of the performance shares or on the period over which the personnel expenses are allocated.

2021 Performance Share Unit Program

On April 1, 2021, MorphoSys established a performance share unit program (PSU program) for the Management Board and certain employees of the Company (beneficiaries). The program is considered a cash-settled, share-based payment and is accounted for accordingly. The PSU program is a performance-based program and is paid out in cash subject to the fulfillment of predefined performance criteria. The grant date was April 19, 2021; the vesting period/performance period is four years. If the predefined performance criteria for the four-year period are fully met, 100% of the performance share units become vested in the four-

year vesting period. The number of performance share units to be vested is calculated on the basis of the performance criteria of the absolute share price development of the MorphoSys share, the relative development of the MorphoSys share price compared to the EURO STOXX Total Market Pharmaceuticals & Biotechnology Index and an assessment of the employee engagement. The performance criteria can be met up to a maximum of 200%. If the defined performance criteria are met by less than 0%, no performance share units will be earned for the four-year assessment period. The right to receive a certain cash settlement from the PSU program does not arise until the end of the four-year vesting period/performance period. After the end of the four-year vesting period, there is a three-month period during which the earned performance shares are transferred from the Company to the beneficiaries by means of a cash settlement.

MorphoSys reserves the right to settle the PSU program at the end of the vesting period in MorphoSys AG's ordinary shares equal to the amount of the performance share units earned. The currently available treasury stocks are likely not sufficient to settle the vested awards. MorphoSys therefore accounts for the plan as a cash-settled share-based payment in accordance with IFRS 2.

In the event of a departure from the Company, beneficiaries generally retain the performance share units that have vested by the time of their departure.

In the event of the termination of a beneficiary's employment for reasons of conduct, or a revocation of the appointment of a member of the Management Board for reasons constituting good cause as defined by Section 626 (2) of the German Civil Code (BGB), all performance share units are forfeited without entitlement to compensation.

If an accumulated period of absence of more than 12 months occurs during the four-year vesting period/performance period, 1/48 of the performance share units are forfeited for each month of absence. A period of absence is defined as an absence due to illness or a period of inactive service or employment without continued payment of remuneration.

If a change of control occurs during the four-year vesting period, all performance share units will become fully vested. In this case, the right to receive a specific allocation of performance share units under the PSU program occurs only at the end of the four-year vesting period.

As of April 1, 2021, a total of 122,005 performance share units were granted to beneficiaries, of which 54,232 performance share units to the Management Board, 12,340 performance share units to other members of the Executive Committee and 55,433 performance share units to certain employees of the Company who are not members of the Management Board or Executive Committee. For the calculation of the personnel expenses from share-based compensation, it was assumed for the PSU program 2021 that 15 beneficiaries would leave the Company during the four-year period.

The fair value of the performance share units of the 2021 Performance Share Unit Program is determined using a Monte Carlo simulation. The expected volatility is based on the development of the share price volatility of the past four years. The calculation of fair values equally considered the performance criteria of the absolute performance of MorphoSys shares, the relative performance compared to the EURO STOXX Total Market Pharmaceuticals & Biotechnology Index, and an evaluation of employee engagement. The parameters of the program are listed in the table below.

	Performance Share Unit Program from April 2021
Share Price in € on June 30, 2021	65.42
Exercise Price in €	n/a
Expected Volatility of the MorphoSys share in %	43.44
Expected Volatility of the EURO STOXX Total Market Pharmaceuticals & Biotechnology Index in %	21.09
Remaining Performance Term of Program in Years	3.75
Dividend Yield in %	n/a
Risk-free Interest Rate in %	(0.66)
Fair Value on June 30, 2021, in €	40.81

9. MorphoSys US Inc. – 2021 Long-Term Incentive Plan

On April 1, 2021, MorphoSys established a Long-Term Incentive Plan (LTI Plan) for certain employees of MorphoSys US Inc. (beneficiaries). According to IFRS 2, this program is considered a share-based payment program with settlement in equity instruments and is accounted for accordingly. The LTI Plan is a performance-related share plan (Restricted Stock Unit Plan - RSUP) and is paid out in shares of MorphoSys AG created from authorized capital when predefined key performance criteria are achieved. The plan has a term of three years and comprises three performance periods with a term of one year each. If the predefined performance criteria for the respective period are fully met, 33.3% of the performance shares become vested in each year. The number of shares vested per year is calculated based on key performance criteria of MorphoSys US Inc. and the share price performance of MorphoSys AG during the annual performance period. The performance criteria can be met annually up to a maximum of 125%. If the specified performance criteria are met by less than 0% in one year, no shares will be earned for that year. After the end of the total three-year performance period, the final number of shares vested is calculated, and the shares created through authorized capital are transferred from the Company to the beneficiaries.

MorphoSys reserves the right to pay a certain amount of the LTI Plan in cash equal to the amount of the performance shares at the end of the performance period.

If a beneficiary ceases to hold office or is no longer employed at MorphoSys US Inc. before the end of a performance period, the beneficiary is generally entitled to all restricted stock units that have vested for previously completed one-year performance periods. All other restricted stock units will be forfeited without compensation.

The fair value of the restricted stock units granted according to the reporting date for the three performance periods amounted to € 65.42 per share on June 30, 2021.

As of April 1, 2021, U.S. beneficiaries had been granted 67,724 restricted shares. In the period from April 1, 2021 to June 30, 2021, eight U.S. beneficiaries have left MorphoSys US Inc., and therefore 8,612 restricted shares have expired. For the 2021 LTI Plan, the calculation of personnel expenses from share-based compensation was based on the assumption that 32 beneficiaries would leave the Company during the three-year period.

10. Personnel Expenses Resulting From Share-Based Payments

In the first six months of 2021, personnel expenses resulting from share-based payments totaling € 1.8 million were recognized on the income statement (H1 2020: € 4.4 million). In 2021, this amount resulted from share-based payments settled with equity instruments and cash compensation. Of this amount, € - 0.2 million was related to personnel expenses from LTI programs (H1 2020: € 0.7 million), € 1.0 million (H1 2020: € 1.9 million) to stock options, € 0.4 million (H1 2020: € 1.2 million) to restricted stock units and € 0.5 million (H1 2020: € 0.6 million) to performance share units. The income from the LTI programs resulted from the reversal of personnel expenses for claims of former beneficiaries that will not be fulfilled anymore. The provision for performance share units amounts to € 0.5 million as of June 30, 2021 (December 31, 2020: € 0.6 million).

11. Managers' Transactions

The Group engages in business relationships with its Management Board and Supervisory Board members as related parties. In addition to cash compensation, the Company has granted performance share units to members of the Management Board.

The tables below show the shares, stock options and performance shares held by the members of the Management and Supervisory Boards, as well as the changes in the members' ownership in the first six months of 2021.

Shares

	01/01/2021	Additions	Sales	06/30/2021
Management Board				
Dr. Jean-Paul Kress	0	0	0	0
Sung Lee ¹	-	250	0	250
Dr. Malte Peters	3,313	4,143	0	7,456
Dr. Roland Wandeler	0	0	0	0
Total	3,313	4,393	0	7,706
Supervisory Board				
Dr. Marc Cluzel	750	250	0	1,000
Michael Brosnan	0	3,750	0	3,750
Sharon Curran	0	0	0	0
Dr. George Golumbeski	0	0	0	0
Wendy Johnson	500	63	0	563
Krisja Vermeylen	350	300	0	650
Total	1,600	4,363	0	5,963

Stock Options

	01/01/2021	Additions	Forfeitures	Exercises	06/30/2021
Management Board					
Dr. Jean-Paul Kress	81,989	0	0	0	81,989
Sung Lee ¹	-	0	0	0	0
Dr. Malte Peters	33,110	0	0	0	33,110
Dr. Roland Wandeler	0	0	0	0	0
Total	115,099	0	0	0	115,099

Performance Shares

	01/01/2021	Additions	Adjustment due to Performance Criteria ²	Forfeitures	Allocations ³	06/30/2021
Management Board						
Dr. Jean-Paul Kress	0	0	0	0	0	0
Sung Lee ¹	-	0	0	0	0	0
Dr. Malte Peters	9,047	0	(1,799)	0	4,143	3,105
Dr. Roland Wandeler	0	0	0	0	0	0
Total	9,047	0	0	0	4,143	4,904

¹ Sung Lee joined the Management Board of MorphoSys AG on February 2, 2021.

² Adjustment due to established performance criteria. For performance criteria that have not yet been met, a target achievement of 100 % is assumed.

³ Allocations are made as soon as performance shares are transferred within the six-month exercise period after the end of the four-year waiting period.

Members of the MorphoSys AG Supervisory Board do not hold any stock options, convertible bonds or performance shares.

12. Transactions with Related Parties

With the exception of the transactions explained under "Managers' Transactions," there were no other related party transactions carried out in the first six months of 2021.

At June 30, 2021, the members of the Executive Committee (excluding the Management Board) held 16,996 stock options and 1,865 performance shares granted by the Company. In 2021, a new program of performance shares was issued to the members of the Executive Committee (excluding the Management Board).

On April 1, 2021, 2,030 shares from the 2017 LTI program were granted to the members of the Executive Committee (excluding the Management Board) with an option to receive these shares within six months. By June 30, 2021, the option for 2,030 shares had been exercised. In addition, members of the Executive Committee (excluding the Management Board) were granted 4,018 options from the 2017 SOP Plan, for which there was an option to exchange them for shares within three years. By June 30, 2021, the option had not been exercised.

13. Further Significant Events and Transactions

By virtue of MorphoSys' business model, the COVID-19 pandemic has had limited impact on MorphoSys' net assets and financial position in the first six months of 2021. The COVID-19 pandemic, however, has had a negative impact on the results of operations in the first six months of 2021, specifically on lower than expected sales of Monjuvi[®]. In addition, the adherence to the time schedule of the clinical studies was associated with higher expenses. There were no material asset impairments that would have to be recognized in connection with COVID-19.

On June 2, 2021, MorphoSys entered into an agreement with Constellation Pharmaceuticals, Inc., (Cambridge, Massachusetts, USA) ("Constellation") under which MorphoSys will acquire Constellation for US\$ 34.00 per share in cash. A merger agreement between MorphoSys and Constellation was also signed on this date. Simultaneously, a royalty purchase agreement, a revenue participation agreement and an equity purchase agreement were entered into between MorphoSys and Royalty Pharma Investments 2019 ICAV, a subsidiary of Royalty Pharma plc (New York, New York, USA) ("Royalty Pharma"). In addition, on the same day, MorphoSys signed a development funding bond agreement with Royalty Pharma USA, Inc. ("Royalty Pharma USA"). The consummation of the tender offer and all agreements was subject to various conditions, including a minimum tender offer of at least a majority of the outstanding Constellation shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and the receipt of all approvals or clearances required to be obtained under applicable antitrust laws, as well as other customary conditions.

By letter dated June 10, 2021, MorphoSys was notified by a licensor of the initiation of arbitration proceedings in the United States. The licensor alleges breach of contract and claims damages for the licensor's argued loss of revenues. Despite the patent expiry in 2018 confirmed by the licensor at the time, this is now disputed and a significantly longer patent term is assumed. Taking into account the associated legal and consulting costs, the potential amount in dispute in the proceedings is in the low double-digit million range and also includes a currently unspecified share of royalty income. A decision by the arbitration court is expected in mid-2022. Based on the current assessment of the facts, MorphoSys believes that the arguments presented are unfounded and that the arbitration will likely be decided in MorphoSys's favor.

On June 16, 2021, MorphoSys made a cash tender offer to purchase all of the outstanding shares of Constellation for US\$ 34.00 per share, which ended on July 14, 2021.

On June 30, 2021, the waiting period for the tender offer for Constellation under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired.

In the context of the acquisition of Constellation and the closing of the related agreements with Royalty Pharma and Royalty Pharma USA, which both became effective on July 15, 2021, directly attributable transaction costs in the amount of € 19.6 million were incurred until June 30, 2021. Of these, € 18.8 million have been expensed and € 0.8 million are presented in other assets as they are to be deducted from equity or liability items to be recognized for the first time in subsequent periods.

14. Subsequent Events

On July 15, 2021, MorphoSys announced the completion of the acquisition of the shares of Constellation on that day. This transaction had a variety of objectives, including strengthening the position in hematology-oncology and expanding research and development capabilities. As a result, the following contractual arrangements have taken effect:

- The cash tender offer to acquire all outstanding shares of Constellation for US\$ 34.00 per share (equivalent to € 28.79) expired at the end of July 14, 2021. A total of 42,811,957 shares with a total value of US\$ 1,455,606,538 (equivalent to € 1,232,624,725) were acquired under this offer by MorphoSys Development Inc. This represents approximately 89% of Constellation's total outstanding 48,094,531 shares. The shares of the approximately 11% remaining shareholders were also acquired after the merger in the context of an automatic squeeze-out on July 15, 2021 at the same price per share in the amount of US\$ 34.00 (equivalent to € 28.79).
- After the acquisition, Constellation was merged into MorphoSys Development Inc. in accordance with the merger agreement. As a result, Constellation as well as its sole subsidiary Constellation Securities Corp. became a wholly direct and indirect owned subsidiary of MorphoSys US Inc. and will be included in the scope of consolidation of MorphoSys AG as of July 15, 2021.

The acquisition date of July 15, 2021 is the decisive date for the accounting for this business combination. The accounting for the business combination will be completed no later than one year after the date of acquisition. A valuation in connection with the allocation of the transaction price to the assets acquired and liabilities assumed has not yet been completed. As a result, no information can currently be provided on the fair values of the assets acquired and liabilities assumed, or on any resulting goodwill. A majority of the transaction price is expected to be allocated to the acquired intangible assets pelabresib and CPI-0209.

The acquisition of Constellation was financed by the cash inflows from Royalty Pharma in the amount of US\$ 1.425 billion (equivalent to € 1.207 billion) as well as with cash and investments from MorphoSys and Constellation.

- The acquisition of Constellation also triggered the effectiveness of the royalty purchase agreement and the revenue participation agreement with Royalty Pharma on July 15, 2021. In accordance with these agreements, Royalty Pharma made non-refundable payments of US\$ 1.3 billion (equivalent to € 1.1 billion) to MorphoSys and US\$ 125.0 million (equivalent to € 105.9 million) to Constellation.

In return, MorphoSys has agreed in the royalty purchase agreement to pass on the following to Royalty Pharma: 100% of MorphoSys' entitlement for royalties from net sales of Tremfya from Janssen, 80% of future royalties, as well as 100% of the future milestone payments for otilimab from GSK and 60% of future royalties for gantenerumab from Roche. Constellation will pass on 3% of future net sales of clinical-stage compounds pelabresib and CPI-0209 to Royalty Pharma based on the revenue participation agreement.

These obligations result in a financial liability from financing for both MorphoSys and Constellation, which will be recognized at amortized cost. The measurement is initially at fair value and subsequently based on the effective interest method.

The contractual provisions stipulate that all royalties for Tremfya from Janssen will be passed on to Royalty Pharma as early as April 1, 2021. The corresponding liability however was recognized on the balance sheet for the first time on July 15, 2021.

In addition, Royalty Pharma has agreed in the equity purchase agreement to acquire shares in MorphoSys for an amount of up to US\$ 100.0 million, or a maximum of 3,289,004 shares. For this reason, MorphoSys executed a capital increase from Authorized Capital 2021-II on July 16, 2021 by resolution of the Management Board and the Supervisory Board. The capital increase resulted in 1,337,552 newly created shares (nominal value of € 1,337,552) to be traded on the Frankfurt Stock Exchange. The shares are

expected to be entered into the commercial register on July 29, 2021, at which time the capital increase will become effective. The proceeds from the capital increase amounted to € 84.7 million, equal to € 63.35 per share.

- On July 15, 2021, the development funding bond agreement with Royalty Pharma USA became effective. Under the terms of this agreement, MorphoSys must draw at least US\$ 150.0 million (equivalent to € 127.0 million) and can draw down a maximum of US\$ 350.0 million (equivalent to € 296.4 million) within one year. Repayment will be made at 2.2 times the amount drawn according to a fixed payment schedule within ten years and nine months starting with a drawdown. To date, no partial amount of the bond has been called.

Responsibility Statement

“To the best of our knowledge, and in accordance with the applicable accounting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the Group’s net assets, financial position and results of operations, and the group interim management report provides a fair view of the development and performance of the business and the position of the Group together with a description of the principal opportunities and risks associated with the Group’s expected development during the remainder of the financial year.”

Planegg, July 27, 2021

Dr. Jean-Paul Kress
Chief Executive Officer

Sung Lee
Chief Financial Officer

Dr. Malte Peters
Chief Research and Development Officer

Dr. Roland Wandeler
Chief Operating Officer

Auditor's Review Report

To MorphoSys AG, Planegg:

We have reviewed the condensed consolidated interim financial statements - comprising the consolidated income statement, consolidated statement of comprehensive income, consolidated balance sheet, consolidated statement of changes in stockholders' equity, consolidated statement of cash flows and notes to the interim consolidated financial statements - and the interim group management report of MorphoSys AG for the period from January 1 to June 30, 2021, which are part of the half-year financial report pursuant to Article 115 WpHG ("Wertpapierhandelsgesetz": German Securities Trading Act). The preparation of the condensed consolidated interim financial statements in accordance with the IFRS applicable to interim financial reporting as adopted by the EU and of the interim group management report in accordance with the provisions of the German Securities Trading Act applicable to interim group management reports is the responsibility of the parent Company's Management Board. Our responsibility is to issue a review report on the condensed consolidated interim financial statements and on the interim group management report based on our review.

We conducted our review of the condensed consolidated interim financial statements and the interim group management report in accordance with German generally accepted standards for the review of financial statements promulgated by the Institut der Wirtschaftsprüfer (Institute of Public Auditors in Germany) (IDW). Those standards require that we plan and perform the review so that we can preclude through critical evaluation and with moderate assurance that the condensed consolidated interim financial statements have not been prepared, in all material respects, in accordance with the IFRS applicable to interim financial reporting as adopted by the EU and that the interim group management report has not been prepared, in all material respects, in accordance with the provisions of the German Securities Trading Act applicable to interim group management reports. A review is limited primarily to inquiries of Company personnel and analytical procedures and therefore does not provide the assurance attainable in a financial statement audit. Since, in accordance with our engagement, we have not performed a financial statement audit, we cannot express an audit opinion.

Based on our review, no matters have come to our attention that lead us to presume that the condensed consolidated interim financial statements have not been prepared, in all material respects, in accordance with the IFRS applicable to interim financial reporting as adopted by the EU or that the interim group management report has not been prepared, in all material respects, in accordance with the provisions of the German Securities Trading Act applicable to interim group management reports.

Munich, July 27, 2021

PricewaterhouseCoopers GmbH
Wirtschaftsprüfungsgesellschaft

Stefano Mulas
Wirtschaftsprüfer (German Public Auditor)

Holger Lutz
Wirtschaftsprüfer (German Public Auditor)

Imprint

MorphoSys AG

Semmelweisstr. 7

82152 Planegg

Germany

Tel.: +49-89-89927-0

Fax: +49-89-89927-222

Email: info@morphosys.com

Website: www.morphosys.com

Investor Relations

Tel.: +49-89-89927-404

Fax: +49-89-89927-5404

Email: investors@morphosys.com

Published on July 28, 2021

This Half-Year Report is also available in German and can be downloaded from the Company's website (PDF). For better readability, this report uses the masculine form only but refers equally to all genders.

Translation

Klusmann Communications, Niedernhausen

Produced in-house using firesys

HuCAL[®], HuCAL GOLD[®], HuCAL PLATINUM[®], CysDisplay[®], RapMAT[®], arYla[®], Ylanthia[®], 100 billion high potentials[®], Slonomics[®], CyCAT[®], MONJUVI[®] and ENFORCER[®] are registered trademarks of the MorphoSys Group. Tremfya[®] is a registered trademark of Janssen Biotech, Inc. XmAb[®] is a registered trademark of Xencor Inc.

Financial Calendar 2021

March 15, 2021	Publication of 2020 Year-End Results
May 5, 2021	Publication of 2021 First Quarter Interim Statement
May 19, 2021	2021 Annual General Meeting
July 28, 2021	Publication of 2021 Half-Year Report
November 10, 2021	Publication of 2021 Third Quarter Interim Statement

MorphoSys AG
Simmelweisstr. 7
82152 Planegg
Germany
Tel.: +498989927-0
Fax: +498989927-222
www.morphosys.com